People with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients, says a new paper published in Nature.
Squamous cell lung cancer kills more people each year than breast, colorectal, or prostate cancer, ranking second only to lung adenocarcinoma in the number of deaths it causes. But unlike the most common form of lung cancer, stem cell carcinoma has no treatments aimed at the specific genetic alterations that drive it....
People with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients, says a new paper published in Nature.
Squamous cell lung cancer kills more people each year than breast, colorectal, or prostate cancer, ranking second only to lung adenocarcinoma in the number of deaths it causes. But unlike the most common form of lung cancer, stem cell carcinoma has no treatments aimed at the specific genetic alterations that drive it....